BriaCell Therapeutics Corp.’s Post

In BriaCell’s Phase 2 clinical study, patients treated with the same Bria-IMT™ regimen formulation being used in the ongoing Phase 3 pivotal trial experienced a one-year survival rate of 55%. This rate exceeds the survival data of the current standard of care for similar patients (see the image below). https://bit.ly/4fb75rw #breastcancer #noveltherapies #cancertherapies #cancerimmunotherapies #oncology #immunotherapies #cancerawareness #cancer #research #biotechnology #cancervaccines #vaccines #innovativetherapies #novelimmunotherapies #cancerdrugs #noveldrugs #MBC #cancertreatments #personalizedcancerimmunotherapies #personalizedcancerdrugs #breastcancer

President and CEO, Dr. William V. Williams, underscores the promise of BriaCell's Bria-IMT™ combination regimen, emphasizing its tolerability profile and outstanding clinical activity in heavily pre-treated patients who failed other therapeutic options. https://bit.ly/4fbDRIO #SABCS24 #metastaticbreastcancer #noveltherapies #cancertherapies #cancerimmunotherapies #oncology #immunotherapies #cancerawareness #cancer #research #biotechnology #cancervaccines #vaccines #innovativetherapies #novelimmunotherapies #cancerdrugs #noveldrugs #MBC #cancertreatments #personalizedcancerimmunotherapies #personalizedcancerdrugs

BriaCell (Nasdaq: BCTX, BCTXW) (TSX: BCT) announces new positive survival data, outperforming patients, and survival rates in its Phase 2 #metastaticbreastcancer study. For additional information, please visit: https://bit.ly/4fb75rw #breastcancer #noveltherapies #cancertherapies #cancerimmunotherapies #oncology #immunotherapies #cancerawareness #cancer #research #biotechnology #cancervaccines #vaccines #innovativetherapies #novelimmunotherapies #cancerdrugs #noveldrugs #MBC #cancertreatments #personalizedcancerimmunotherapies #personalizedcancerdrugs #breastcancer

Median overall survival of 15.6 months is reported in BriaCell’s most recent Phase 2 Bria-IMT™ study patients (treated since 2022) vs. 6.7-9.3 months for similar patients reported in the literature. Please see the table below and visit our site for more information. https://bit.ly/3MHZDrQ #metastaticbreastcancer #breastcancer #noveltherapies #cancertherapies #cancerimmunotherapies #oncology #immunotherapies #cancerawareness #cancer #research #biotechnology #cancervaccines #vaccines #innovativetherapies #novelimmunotherapies #cancerdrugs #noveldrugs #MBC #cancertreatments

BriaCell’s Chief Medical Officer, Dr. Giuseppe Del Priore, underscores the significance of the positive DSMB review, reinforcing the Company's confidence in the potential use of the BriaCell combination regimen in #metastaticbreastcancer patients. Read more: https://bit.ly/3ZxPh4U #breastcancer #noveltherapies #cancertherapies #cancerimmunotherapies #oncology #immunotherapies #cancerawareness #cancer #research #biotechnology #cancervaccines #vaccines #innovativetherapies #novelimmunotherapies #cancerdrugs #noveldrugs #MBC #cancertreatments

Five BriaCell posters (four today and one on Dec 13th) showcase robust survival and clinical benefit data, plus key biomarker data from Phase 2 trial of Bria-IMT™ in #metastaticbreastcancer (#MBC). https://bit.ly/4fbDRIO #SABCS24 #breastcancer #noveltherapies #cancertherapies #cancerimmunotherapies #oncology #immunotherapies #cancerawareness #cancer #research #biotechnology #cancervaccines #vaccines #innovativetherapies #novelimmunotherapies #cancerdrugs #noveldrugs #MBC #cancertreatments #personalizedcancerimmunotherapies #personalizedcancerdrugs

Dr. William V. Williams, BriaCell’s President & CEO, highlights the dramatic anti-tumor response reported in a patient treated in the Phase 2 study of BriaCell’s Bria-IMT™ regimen. Learn more: https://bit.ly/3zOcpSw #breastcancer #noveltherapies #cancertherapies #cancerimmunotherapies #oncology #immunotherapies #cancerawareness #cancer #research #biotechnology #cancervaccines #vaccines #innovativetherapies #novelimmunotherapies #cancerdrugs #noveldrugs #MBC #cancertreatments

Giuseppe Del Priore, MD, MPH, BriaCell’s CMO, provides insights on the company's positive overall survival data of Phase 2 Bria-IMT™ study in #metastaticbreastcancer. https://bit.ly/3MHZDrQ #metastaticbreastcancer #breastcancer #noveltherapies #cancertherapies #cancerimmunotherapies #oncology #immunotherapies #cancerawareness #cancer #research #biotechnology #cancervaccines #vaccines #innovativetherapies #novelimmunotherapies #cancerdrugs #noveldrugs #MBC #cancertreatments

BriaCell President and CEO, Dr. William V. Williams, highlights the positive overall survival benefit in late stage #metastaticbreastcancer patients being treated with BriaCell’s Bria-IMT™ combination regimen. Learn more: https://bit.ly/3MHZDrQ #metastaticbreastcancer #breastcancer #noveltherapies #cancertherapies #cancerimmunotherapies #oncology #immunotherapies #cancerawareness #cancer #research #biotechnology #cancervaccines #vaccines #innovativetherapies #novelimmunotherapies #cancerdrugs #noveldrugs #MBC #cancertreatments

The Data Safety Monitoring Board (DSMB) stated no safety concerns, and recommended continuation of BriaCell’s pivotal Phase 3 study of Bria-IMT™ + CPI in #metastaticbreastcancer. Learn more from our President & CEO, Dr. William V. Williams: https://bit.ly/3ZxPh4U #breastcancer #noveltherapies #cancertherapies #cancerimmunotherapies #oncology #immunotherapies #cancerawareness #cancer #research #biotechnology #cancervaccines #vaccines #innovativetherapies #novelimmunotherapies #cancerdrugs #noveldrugs #MBC #cancertreatments #personalizedcancerimmunotherapies #personalizedcancerdrugs